Education
About Us
Working with TipRanks
Follow Us
Mural Oncology Plc (MURA)
NASDAQ:MURA
MURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.87 - $5.12
Previous CloseN/A
Volume157.34K
Average Volume (3M)112.96K
Market Cap
$65.98M
Enterprise Value-$112.66M
Total Cash (Recent Filing)$115.46M
Total Debt (Recent Filing)$8.02M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
May 20, 2025EPS Estimate
-1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.58
Shares Outstanding17,228,290
10 Day Avg. Volume118,653
30 Day Avg. Volume112,962
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
$12.00Price Target Upside213.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMural Oncology remains on track to release interim overall survival data from the potentially registrational Phase 3 ARTISTRY-7 study in patients with platinum-resistant ovarian cancer by late Q1/early Q2 2025.
Financial PerformanceCash runway guidance into 1Q26 was reiterated, indicating financial stability.
Product DifferentiationNemvaleukin is a highly differentiated IL-2 fusion protein that blocks adverse event seen from this drug class, stops proliferation of immune dampening T cell types and activates tumor killing NK and T cells.
Bears Say
Clinical Trials OutcomeInterim survival analysis failed to show any improvement in survival with treatment over control arm in platinum resistant ovarian cancer.
Study OutcomeBased on the pre-specified interim analysis conducted by the independent data monitoring committee, the company believes the study is highly unlikely to achieve success at the final analysis.
Study TerminationMural will not progress trial to final analysis and will cease development of the treatment for platinum resistant ovarian cancer.
---
Ownership Overview
3.40% Insiders
7.22% Mutual Funds
36.81% Other Institutional Investors
47.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MURA FAQ
What was Mural Oncology Plc’s price range in the past 12 months?
Mural Oncology Plc lowest stock price was $2.87 and its highest was $5.12 in the past 12 months.
What is Mural Oncology Plc’s market cap?
Mural Oncology Plc’s market cap is $65.98M.
When is Mural Oncology Plc’s upcoming earnings report date?
Mural Oncology Plc’s upcoming earnings report date is May 20, 2025 which is in 55 days.
How were Mural Oncology Plc’s earnings last quarter?
Mural Oncology Plc released its earnings results on Mar 11, 2025. The company reported -$2.01 earnings per share for the quarter, missing the consensus estimate of -$1.988 by -$0.022.
Is Mural Oncology Plc overvalued?
According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued.
Does Mural Oncology Plc pay dividends?
Mural Oncology Plc does not currently pay dividends.
What is Mural Oncology Plc’s EPS estimate?
Mural Oncology Plc’s EPS estimate is -1.86.
How many shares outstanding does Mural Oncology Plc have?
Mural Oncology Plc has 17,228,290 shares outstanding.
What happened to Mural Oncology Plc’s price movement after its last earnings report?
Mural Oncology Plc reported an EPS of -$2.01 in its last earnings report, missing expectations of -$1.988. Following the earnings report the stock price went down -1.842%.
Which hedge fund is a major shareholder of Mural Oncology Plc?
Currently, no hedge funds are holding shares in MURA
---
Mural Oncology Plc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (213.32% Upside)
$12.00 (213.32% Upside)
Blogger Sentiment
Bullish
MURA Sentiment 70%
Sector Average 76%
Sector Average 76%
Hedge Fund Trend
Decreased
By 800.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.07%
12-Months-Change
Fundamentals
Return on Equity
-63.57%
Trailing 12-Months
Asset Growth
-43.86%
Trailing 12-Months
Company Description
Mural Oncology Plc
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
---
MURA Stock 12 Month Forecast
Average Price Target
$12.00
▲(213.32% Upside)
Technical Analysis
Best Analysts Covering MURA
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+5.03%
reiterated a buy rating 15 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +5.03% per trade.
---